Columnist Sam Kirton describes how daunting an IPF prognosis can be — but also how things are looking up for patients today.

IPF treatment candidate CS014 was safe and well tolerated in volunteers in a Phase 1 trial, and showed early promise for ...

Taladegib has been granted orphan drug designation in the U.S. and the European Union as a treatment for idiopathic pulmonary ...

A flash flood can pose unique risks for PF patients, says columnist Sam Kirton, who shares several ways to prepare for such an emergency.

Looking for information on Shallow Breathing (Tachypnea) in pulmonary fibrosis? Read about breathing alterations in IPF here.

Fatigue, sometimes described as overwhelming tiredness or physical malaise, is a common symptom of pulmonary fibrosis (PF) patients. Generally, fatigue is characterized by a lack of energy that does ...

Pulmonary fibrosis (PF) is characterized by the formation of scar tissue in the lungs, which impairs their normal function and makes it harder for oxygen to reach the bloodstream. Despite varying from ...

For pulmonary fibrosis patients, lung transplant is often the best choice for extending life and improving quality of life. Because PF is a progressive disease with no current cure, the lungs ...

The U.S. Food and Drug Administration has granted Bristol Myers Squibb’s investigational therapy BMS-986278 breakthrough therapy status.